Literature DB >> 20388894

2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore.

Mark I C Chen1, Vernon J M Lee, Wei-Yen Lim, Ian G Barr, Raymond T P Lin, Gerald C H Koh, Jonathan Yap, Lin Cui, Alex R Cook, Karen Laurie, Linda W L Tan, Boon Huan Tan, Jimmy Loh, Robert Shaw, Chris Durrant, Vincent T K Chow, Anne Kelso, Kee Seng Chia, Yee Sin Leo.   

Abstract

CONTEXT: Singapore experienced a single epidemic wave of 2009 influenza A(H1N1) with epidemic activity starting in late June 2009 and peaking in early August before subsiding within a month.
OBJECTIVE: To compare the risk and factors associated with H1N1 seroconversion in different adult cohorts. DESIGN, SETTING, AND PARTICIPANTS: A study with serial serological samples from 4 distinct cohorts: general population (n = 838), military personnel (n = 1213), staff from an acute care hospital (n = 558), and staff as well as residents from long-term care facilities (n = 300) from June 22, 2009, to October 15, 2009. Hemagglutination inhibition results of serum samples taken before, during, and after the epidemic and data from symptom questionnaires are presented. MAIN OUTCOME MEASURES: A 4-fold or greater increase in titer between any of the 3 serological samples was defined as evidence of H1N1 seroconversion.
RESULTS: Baseline titers of 40 or more were observed in 22 members (2.6%; 95% confidence interval [CI], 1.7%-3.9%) of the community, 114 military personnel (9.4%; 95% CI, 7.9%-11.2%), 37 hospital staff (6.6%; 95% CI, 4.8%-9.0%), and 20 participants from long-term care facilities (6.7%; 95% CI, 4.4%-10.1%). In participants with 1 or more follow-up serum samples, 312 military personnel (29.4%; 95% CI, 26.8%-32.2%) seroconverted compared with 98 community members (13.5%; 95% CI, 11.2%-16.2%), 35 hospital staff (6.5%; 95% CI, 4.7%-8.9%), and only 3 long-term care participants (1.2%; 95% CI, 0.4%-3.5%). Increased frequency of seroconversion was observed for community participants from households in which 1 other member seroconverted (adjusted odds ratio [OR], 3.32; 95% CI, 1.50-7.33), whereas older age was associated with reduced odds of seroconversion (adjusted OR, 0.77 per 10 years; 95% CI, 0.64-0.93). Higher baseline titers were associated with decreased frequency of seroconversion in community (adjusted OR for every doubling of baseline titer, 0.48; 95% CI, 0.27-0.85), military (adjusted OR, 0.71; 95% CI, 0.61-0.81), and hospital staff cohorts (adjusted OR, 0.50; 95% CI, 0.26-0.93).
CONCLUSION: Following the June-September 2009 wave of 2009 influenza A(H1N1), 13% of the community participants seroconverted, and most of the adult population likely remained susceptible.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20388894     DOI: 10.1001/jama.2010.404

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  89 in total

1.  Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism.

Authors:  Yuan Fang; David Banner; Alyson A Kelvin; Stephen S H Huang; Christopher J Paige; Steven A Corfe; Kevin P Kane; R Chris Bleackley; Thomas Rowe; Alberto J Leon; David J Kelvin
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

2.  Antibody prevalence to the 2009 pandemic influenza A (H1N1) virus in Germany: geographically variable immunity in winter 2010/2011.

Authors:  Anne Hackenberg; Gökhan Arman-Kalcek; Jens Hiller; Gülsah Gabriel
Journal:  Med Microbiol Immunol       Date:  2012-06-10       Impact factor: 3.402

3.  Retrospective investigation of an influenza A/H1N1pdm outbreak in an Italian military ship cruising in the Mediterranean Sea, May-September 2009.

Authors:  Mario Tarabbo; Daniele Lapa; Concetta Castilletti; Pietro Tommaselli; Riccardo Guarducci; Giuditta Lucà; Alessandro Emanuele; Onofrio Zaccaria; Vincenzo F P La Gioia; Enrico Girardi; Maria R Capobianchi; Giuseppe Ippolito
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

4.  Epidemiological characteristics of the influenza A(H1N1) 2009 pandemic in the Western Pacific Region.

Authors:  Lisa McCallum; Jeffrey Partridge
Journal:  Western Pac Surveill Response J       Date:  2010-12-10

5.  Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel.

Authors:  Matthew C Johns; Angelia A Eick; David L Blazes; Seung-eun Lee; Christopher L Perdue; Robert Lipnick; Kelly G Vest; Kevin L Russell; Robert F DeFraites; Jose L Sanchez
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

Review 6.  Reflections on pandemic (H1N1) 2009 and the international response.

Authors:  Gabriel M Leung; Angus Nicoll
Journal:  PLoS Med       Date:  2010-10-05       Impact factor: 11.069

7.  Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009.

Authors:  Vernon J Lee; Jonathan Yap; Joshua K Tay; Ian Barr; Qiuhan Gao; Hanley J Ho; Boon Huan Tan; Paul M Kelly; Paul A Tambyah; Anne Kelso; Mark I Chen
Journal:  BMC Infect Dis       Date:  2010-06-10       Impact factor: 3.090

8.  Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter.

Authors:  Gwendolyn L Gilbert; Michelle A Cretikos; Linda Hueston; George Doukas; Brian O'Toole; Dominic E Dwyer
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

9.  Seroepidemiology of pandemic influenza A (H1N1) 2009 virus infections in Pune, India.

Authors:  Babasaheb V Tandale; Shailesh D Pawar; Yogesh K Gurav; Mandeep S Chadha; Santosh S Koratkar; Vijay N Shelke; Akhilesh C Mishra
Journal:  BMC Infect Dis       Date:  2010-08-25       Impact factor: 3.090

10.  Serological analysis of human pandemic influenza (H1N1) in Thailand.

Authors:  Slinporn Prachayangprecha; Jarika Makkoch; Sunchai Payungporn; Thaweesak Chieochansin; Chanpim Vuthitanachot; Viboonsuk Vuthitanachot; Apiradee Theamboonlers; Yong Poovorawan
Journal:  J Health Popul Nutr       Date:  2010-12       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.